48,470
edits
Difference between revisions of "Inflammatory myofibroblastic tumour"
Jump to navigation
Jump to search
→IHC
(→IHC) |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
| Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification | | Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]], [[gastrointestinal stromal tumour]] | | LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]], [[gastrointestinal stromal tumour]], [[epithelioid inflammatory myofibroblastic sarcoma]] | ||
| Stains = | | Stains = | ||
| IHC = | | IHC = | ||
| Line 37: | Line 37: | ||
*Mostly benign. | *Mostly benign. | ||
*Children & young adults. | *Children & young adults. | ||
May be treated with: | |||
*[[ALK inhibitors]].<ref name=pmid30790150>{{Cite journal | last1 = Honda | first1 = K. | last2 = Kadowaki | first2 = S. | last3 = Kato | first3 = K. | last4 = Hanai | first4 = N. | last5 = Hasegawa | first5 = Y. | last6 = Yatabe | first6 = Y. | last7 = Muro | first7 = K. | title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. | journal = Invest New Drugs | volume = | issue = | pages = | month = Feb | year = 2019 | doi = 10.1007/s10637-019-00742-2 | PMID = 30790150 }}</ref> | |||
*Drugs that act on ROS1 rearrangements, e.g. [[crizotinib]].<ref name=pmid30642440>{{Cite journal | last1 = Mai | first1 = S. | last2 = Xiong | first2 = G. | last3 = Diao | first3 = D. | last4 = Wang | first4 = W. | last5 = Zhou | first5 = Y. | last6 = Cai | first6 = R. | title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. | journal = Lung Cancer | volume = 128 | issue = | pages = 101-104 | month = Feb | year = 2019 | doi = 10.1016/j.lungcan.2018.12.016 | PMID = 30642440 }}</ref> | |||
==Gross== | ==Gross== | ||
| Line 79: | Line 83: | ||
*CD117 -ve. | *CD117 -ve. | ||
**Case report of CD117 +ve.<ref name=pmid24938355/> | **Case report of CD117 +ve.<ref name=pmid24938355/> | ||
*CD30 -ve. | |||
Variable staining with: | Variable staining with: | ||
| Line 88: | Line 93: | ||
==Molecular== | ==Molecular== | ||
*ALK rearrangements.<ref name=pmid21297584/> | *ALK rearrangements.<ref name=pmid21297584/> | ||
*ROS1 rearrangements.<ref name=pmid30642440>{{Cite journal | last1 = Mai | first1 = S. | last2 = Xiong | first2 = G. | last3 = Diao | first3 = D. | last4 = Wang | first4 = W. | last5 = Zhou | first5 = Y. | last6 = Cai | first6 = R. | title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. | journal = Lung Cancer | volume = 128 | issue = | pages = 101-104 | month = Feb | year = 2019 | doi = 10.1016/j.lungcan.2018.12.016 | PMID = 30642440 }}</ref> | |||
==See also== | ==See also== | ||